Background: Chronic hepatitis C virus (HCV) infection is the most frequent cause of progressive liver disease and hepatocellular carcinoma (HCC) in Egypt. Risk of HCC can be affected by the exposure to endogenous or environmental toxins. Genetic polymorphism of the carcinogensmetabolizing enzymes, were suggested as modifiers of cancer risk. So, the present study aimed to investigate the association between xenobiotic metabolizing enzymes [cytochrome P450 (CYP2D6), N-acetyl transferase 2 (NAT2) and UDP-glucuronosyltransferase 1A7 (UGT1A7)] gene polymorphism and the risk of HCC in patients with chronic HCV-induced cirrhosis compared to normal and chronic HCV infected subjects. Subjects and Methods: 354 subjects, divided into 3 groups, (group I: 150 patients had chronic hepatitis C with HCC, group II: 104 patients had chronic hepatitis C without HCC and group III: 100 healthy controls. The studied genes were genotyped using polymerase chain reaction-restriction fragment length polymorphism and allelic discrimination assays. Results: CYP2D6*6 and CYP2D6*3 poor metabolizers (homozygous mutant genotypes) were significantly increased in HCC patients compared to controls and were associated with increased HCC risk with ORs and 95%CI of 4.0 (2.5-6.4) and 3.32 (2.1-5.2) respectively. Meanwhile, CYP2D 6*4 extensive metabolizer (homozygous wild genotypes; GG) was significantly increased in HCC patients compared to controls and was associated with increased HCC risk with ORs and 95%CI of 2.3 (1.42-3.85). However homozygous mutant genotypes (slow acetylators) of NAT2 M1, M2 and M3 showed no significant difference between HCC patients and controls and were not associated with increased HCC risk. Also, genotypes of UGT1A7 gene showed no significant difference in HCC patients compared to other groups and had no effect on HCC susceptibility. Conclusion: Poor metabolizers' genotypes of CYP2D 6*6 and CYP2D 6*3 and extensive metabolizer genotypes of CYP2D 6*4 may be risk factors for HCC in patients infected with HCV. Meanwhile, NAT2 and UGT1A7 genes polymorphism were not associated with increased risk of HCC in the studied patients.
Introduction
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and its incidence is increasing (1) . In Egypt, due to the high prevalence of HCV and HBV infections, the incidence rate of HCC has doubled in the past ten years (2) . A decrease in carcinogen metabolism and an increase in procarcinogen activation have also been documented as HCC risk factors (3) . CYP2D6 is the most extensively studied polymorphically expressed drug metabolizing enzyme in humans. As a result of the presence of more than 70 allelic variants of CYP2D6 Gene (6), metabolism and excretion rates of drugs vary between individuals, from extremely slow to ultrafast (7) . 
N-acetyl transferase-2 (NAT-
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Subjects and Methods
This work was carried out in accordance with The Corporation, Erlangen, Germany) respectively.
Genotyping
Genomic DNA was extracted from EDTA-treated whole blood using Gene JET Whole Blood Genomic DNA Purification Mini Kit, (Thermo Fisher Scientific, MA USA). All primers used in this study were synthesized at Metabion international AG, Martinsried, Germany.
I. NAT 2
Genotyping of NAT2*5(Ml allele) (C481T) 
III. Cytochrome P450 (CYP2D6) Gene Polymorphisms
The allelic discrimination of the CYP2D6*3, 
Results
The mean age for HCC patients was 53.7 ± 7.80 years and 80% were males, for CHC patients; it was 45.01 ± 5.5 years and 78.80% were males and for healthy subjects it was 43.2 ± 4.6 years and 77% were male.
Demographic data of the HCC group were shown in 
